In the last trading session, 7.66 million Editas Medicine Inc (NASDAQ:EDIT) shares changed hands as the company’s beta touched 1.91. With the company’s per share price at $2.01 changed hands at $0.09 or 4.69% during last session, the market valuation stood at $165.92M. EDIT’s last price was a discount, traded about -476.12% off its 52-week high of $11.58. The share price had its 52-week low at $1.12, which suggests the last value was 44.28% up since then.
Analysts gave the Editas Medicine Inc (EDIT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.62. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended EDIT as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Editas Medicine Inc’s EPS for the current quarter is expected to be -0.33.
Editas Medicine Inc (NASDAQ:EDIT) trade information
Instantly EDIT was in green as seen at the end of in last trading. With action 45.65%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 58.27%, with the 5-day performance at 45.65% in the green. However, in the 30-day time frame, Editas Medicine Inc (NASDAQ:EDIT) is 42.55% up.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 77.67% from its current market value. According to analyst projections, EDIT’s forecast low is 5 with 10 as the target high. To hit the forecast high, the stock’s price needs a -397.51% plunge from its current level, while the stock would need to soar -148.76% for it to hit the projected low.
Editas Medicine Inc (EDIT) estimates and forecasts
Year-over-year growth is forecast to reach -47.32% down from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 37.17M. 4 analysts are of the opinion that Editas Medicine Inc’s revenue for the current quarter will be 640.25k. The company’s revenue for the corresponding quarters a year ago was 60.05M and 1.14M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -38.10%. The estimates for the next quarter sales put growth at -43.59%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 2.88%. The 2025 estimates are for Editas Medicine Inc earnings to decrease by -33.69%, but the outlook for the next 5-year period is at 15.23% per year.
EDIT Dividends
Editas Medicine Inc is expected to release its next quarterly earnings report in March.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 9.498% or 7.78 million shares worth $36.34 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 2.59 shares estimated at $5.21 million under it, the former controlled 3.14% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.83% of the shares, roughly 2.33 shares worth around $4.69 million.
